InGeneron, Inc., a Houston, TX-based regenerative medicine and cell therapy company, received a $20m in Series D financing.
Sanford Health, one of the largest integrated healthcare providers in the U.S., made the investment. The funding is in addition to an active cooperation between InGeneron and Sanford Health for the execution of the company’s clinical programs to improve outcomes in rotator cuff and venous ulcer treatment with its proprietary cell-based therapeutic approach.
Earlier this year, Sanford began enrolling participants in the FDA-approved Safety and Efficacy of Adult Adipose-Derived Stem Cell Injections into Partial Thickness Rotator Cuff Tears clinical trial. The trial uses stromal vascular fraction, a mixture of cells and nutrients isolated from a patient’s own body that contain adipose-derived stem cells, as a potential therapy for partial-thickness rotator cuff tears. Sanford scientists and clinicians are exploring the application of this type of stem cells for other conditions.
Led by Ron Stubbers, MBA, President, and Fabian Alt, CFO, InGeneron is developing regenerative cell therapy applications for orthopedic and wound-healing indications based on its proprietary technology, which enables physicians to use adipose-derived regenerative cells from the patient’s own body for immediate therapeutic application at point of care.